We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    heinrichs oxytocin
Previous Study | Return to List | Next Study

"The Effects of Oxytocin on Patients With Borderline Personality Disorder"

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by Prof. Dr. Markus Heinrichs, University of Freiburg.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: November 18, 2010
Last Update Posted: December 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Prof. Dr. Markus Heinrichs, University of Freiburg
November 17, 2010
November 18, 2010
December 9, 2014
January 2011
August 2014   (Final data collection date for primary outcome measure)
BPD Symptoms [ Time Frame: BPD Symptoms ]
Not Provided
Complete list of historical versions of study NCT01243658 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
"The Effects of Oxytocin on Patients With Borderline Personality Disorder"
Not Provided

RCT. Two substudies (clinical and experimental). Main objective of the trial is to examine if oxytocin, compared to placebo shows any additional effect on the therapy achievements (outcome) of patients with borderline personality disorder, who receive an in-patient standard psychotherapy (Dialectical-behavioral-therapy, Marsha Linehan (2006)).

Secondary objectives :

Investigate if oxytocin compared to placebo enhances social trust and emotion recognition in patients with borderline personality disorder. Comparison of the effects of Oxytocin on patients with BPD and major depression.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Effects of Oxytocin on Borderline Personality Disorder.
Drug: Oxytocin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
January 2016
August 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Gender: Both, male and female
  • Minimum Age: 18 Years
  • Maximum Age: 50 Years
  • Borderline personality disorder or major depression (clinical control group)
  • Mini Mental Status Test > 27 (capacity to consent)

Exclusion Criteria:

  • chronic or acute somatic health problems
  • Schizophrenia
  • Bipolar affective disorder
  • pregnancy
  • breast feeding
  • neurological disorder
  • allergy to antidegradants
Sexes Eligible for Study: All
18 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Prof. Dr. Markus Heinrichs, University of Freiburg
Prof. Dr. Markus Heinrichs
Not Provided
Study Director: Markus Heinrichs, Prof. Dr. Institut für Psychologie der Univeristät Freiburg
University of Freiburg
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP